What is the Medicare GLP-1 Bridge program?

A program by Eli Lilly allowing eligible Medicare Part D patients to access weight management drugs at a flat $50 per month.

Which weight loss drugs are included by Eli Lilly?

The article does not specify drug names, but likely includes GLP-1 drugs like tirzepatide (Mounjaro/Zepbound).

Does Asness' pick constitute a buy recommendation?

No, it reflects his personal view and is not a buy or sell recommendation. Investors should do their own research.

Eli Lilly (LLY) Among Billionaire Cliff Asness' Top Healthcare Picks

Billionaire Cliff Asness has included Eli Lilly and Company (NYSE:LLY) among his top 10 healthcare stock picks. The company also released details of its Medicare GLP-1 Bridge program, offering weight management drugs at a flat $50 per month.

July 1, 2026

2 min read

Source: Insider Monkey

Key Numbers

flat monthly cost

$50

Billionaire Cliff Asness, founder of AQR Capital Management, has selected Eli Lilly and Company (NYSE:LLY) as one of his top 10 healthcare stock picks. This selection comes as Eli Lilly continues to strengthen its position in the weight loss drug market.

Medicare GLP-1 Bridge Program Details

On June 25, Eli Lilly released additional details about the Medicare GLP-1 Bridge program, which aims to improve access to its weight management drugs for eligible Medicare Part D patients. Under the program, patients can access the drugs for a flat $50 per month.

Context

The announcement comes amid rising demand for GLP-1 drugs for obesity and diabetes, with Eli Lilly competing against companies like Novo Nordisk. Asness' pick reflects confidence in the company's growth prospects.

What This Means for Investors

Eli Lilly's inclusion by a prominent investor like Cliff Asness bolsters market confidence. Additionally, the Medicare GLP-1 Bridge program could expand the patient base for weight loss drugs, potentially boosting revenues.

Frequently Asked Questions

Cliff Asness is a billionaire and founder of AQR Capital Management, a quantitative investment firm.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.